54 -3 (89) 2026 - Pulatova Sh., Shodikulova G.Z. - EPIGENETIC MODIFICATION INTO DIABETIC KIDNEY DISEASE

EPIGENETIC MODIFICATION INTO DIABETIC KIDNEY DISEASE

Pulatova Sh. - Bukhara State Medical Institute named after Abu Ali ibn Sina, Samarkand State Medical University

Shodikulova G.Z. - Bukhara State Medical Institute named after Abu Ali ibn Sina, Samarkand State Medical University

Resume

Diabetic kidney disease (DKD) is a common microangiopathy in diabetic patients and the leading cause of death in diabetic patients. The main manifestations of DKD proteinuria and a decrease in renal filtration capacity. Glomerular filtration rate and urinary albumin levels are the two most important features of DBP progression. Classic DBP treatment controls blood glucose and blood pressure. However, frequently used clinical therapeutic strategies and existing biomarkers only partially slow the progression of DKD and roughly predict disease progression. Thus, new therapeutics, targets and biomarkers are urgently needed to meet clinical requirements. In recent years, increasing attention has been paid to the role of epigenetic modification in the pathogenesis of DBP. Epigenetic variation mainly involves DNA methylation, histone modification, and changes in the non-coding RNA expression profile that is deeply involved in DBP-related inflammation, oxidative stress, hemodynamics, and activation of abnormal pathway signaling. Because DKD is reversible at certain stages of the disease, it is useful to identify abnormal epigenetic modifications, such as early diagnosis and treatment of the target to prevent progression to end-stage renal disease (ESRD). Because the current understanding of the epigenetic mechanism of DBP is not comprehensive, the aim of this review is to summarize the role of epigenetic modification in the onset and development of DBP and to assess the value of epigenetic therapy in DKD.

Keywords: epigenetic modification, diabetic kidney disease, metabolic disorder, biomarker, non-coding RNA.

First page

339

Last page

342

For citation:Pulatova Sh., Shodikulova G.Z. - EPIGENETIC MODIFICATION INTO DIABETIC KIDNEY DISEASE//New Day in Medicine 3(89)2026 339-342 https://newdayworldmedicine.com/en/new_day_medicine/3-89-2026

List of References

  1. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UK Prospective Diabetes Study Group. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-1839. doi:10.2337/db05-1620
  2. L'Heveder R, Nolan T. International Diabetes Federation. Diabetes Res Clin Pract. 2013;101(3):349-351. doi:10.1016/j.diabres.2013.08.003
  3. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. doi:10.1038/nrdp.2015.18
  4. Thomas MC. Epigenetic mechanisms in diabetic kidney disease. Curr Diabetes Rep. 2016;16(3):31. doi:10.1007/s11892-016-0723-9
  5. Simeone CA, Wilkerson JL, Poss AM, Banks JA, Varre JV, Guevara JL, et al. A dominant negative ADIPOQ mutation in a diabetic family with renal disease, hypoadiponectinemia, and hyperceramidemia. NPJ Genom Med. 2022;7(1):43. doi:10.1038/s41525-022-00314-z
  6. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359(15):1618-1620. doi:10.1056/NEJMe0807625
  7. Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 2015;58(3):443-455. doi:10.1007/s00125-014-3462-y
  8. Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, et al. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 2014;63(5):1748-1762. doi:10.2337/db13-1251
  9. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, et al. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci USA. 2016;113(21):E3002-E3011. doi:10.1073/pnas.1603712113
  10. Theofilis P, Vordoni A, Tsimihodimos V, Kalaitzidis RG. Metabolic dysfunction-associated fatty liver disease in newly diagnosed, treatment-naive hypertensive patients and its association with cardiorenal risk markers. High Blood Press Cardiovasc Prev. 2023;30(1):63-72. doi:10.1007/s40292-023-00558-5

    file

    download